Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PAI1 mediates fibroblast–mast cell interactions in skin fibrosis
Neha Pincha, … , Paul Mazhuvanchary Jacob, Colin Jamora
Neha Pincha, … , Paul Mazhuvanchary Jacob, Colin Jamora
Published March 26, 2018
Citation Information: J Clin Invest. 2018;128(5):1807-1819. https://doi.org/10.1172/JCI99088.
View: Text | PDF
Research Article Cell biology Inflammation

PAI1 mediates fibroblast–mast cell interactions in skin fibrosis

  • Text
  • PDF
Abstract

Fibrosis is a prevalent pathological condition arising from the chronic activation of fibroblasts. This activation results from the extensive intercellular crosstalk mediated by both soluble factors and direct cell-cell connections. Prominent among these are the interactions of fibroblasts with immune cells, in which the fibroblast–mast cell connection, although acknowledged, is relatively unexplored. We have used a Tg mouse model of skin fibrosis, based on expression of the transcription factor Snail in the epidermis, to probe the mechanisms regulating mast cell activity and the contribution of these cells to this pathology. We have discovered that Snail-expressing keratinocytes secrete plasminogen activator inhibitor type 1 (PAI1), which functions as a chemotactic factor to increase mast cell infiltration into the skin. Moreover, we have determined that PAI1 upregulates intercellular adhesion molecule type 1 (ICAM1) expression on dermal fibroblasts, rendering them competent to bind to mast cells. This heterotypic cell-cell adhesion, also observed in the skin fibrotic disorder scleroderma, culminates in the reciprocal activation of both mast cells and fibroblasts, leading to the cascade of events that promote fibrogenesis. Thus, we have identified roles for PAI1 in the multifactorial program of fibrogenesis that expand its functional repertoire beyond its canonical role in plasmin-dependent processes.

Authors

Neha Pincha, Edries Yousaf Hajam, Krithika Badarinath, Surya Prakash Rao Batta, Tafheem Masudi, Rakesh Dey, Peter Andreasen, Toshiaki Kawakami, Rekha Samuel, Renu George, Debashish Danda, Paul Mazhuvanchary Jacob, Colin Jamora

×

Figure 4

PAI1 mediates mast cell infiltration and increased fibroblast mast cell adhesion.

Options: View larger image (or click on image) Download as PowerPoint
PAI1 mediates mast cell infiltration and increased fibroblast mast cell ...
(A) Quantification of migrating mast cells into buffer or recombinant PAI1–containing media in a Transwell assay (n = 5). Quantification adherent mast cells on newborn dermal fibroblasts after (B) recombinant PAI1 treatment of fibroblast–mast cell cocultures (n = 4) and (C) pretreatment of fibroblasts with buffer, recombinant PAI1, and RGD peptide (n = 3). (D) Immunostaining for surface-bound vitronectin after treatment of fibroblasts with buffer or recombinant PAI1 (n = 3). Scale bar: 50 μm. (E) Quantification of adherent mast cells after pretreatment of fibroblasts with buffer or recombinant PAI1 in the absence or presence of FAK inhibitor (FAK inh) (n = 3). (F) Immunostaining of ICAM1 expression after recombinant PAI1 treatment of fibroblasts in the absence or presence of FAK inhibitor (n = 3). Scale bar: 50 μm. (G) Quantification of adherent mast cells after pretreatment of fibroblasts with buffer or recombinant PAI1 followed by incubation with ICAM1 inhibitor (ICAM1 inh) or LDV peptide, or with mast cells (MCs) preincubated with LDV peptide (n = 3). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by Student’s t test (A and B) and 1-way ANOVA followed by Tukey’s post hoc analysis (C, E, and G).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts